Syndax Pharmaceuticals Inc
NASDAQ:SNDX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.48
24.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Total Receivables
Syndax Pharmaceuticals Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
Total Receivables
$4.7m
|
CAGR 3-Years
186%
|
CAGR 5-Years
88%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$7.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$6.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Syndax Pharmaceuticals Inc
Glance View
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, engages in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The firm is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.
See Also
What is Syndax Pharmaceuticals Inc's Total Receivables?
Total Receivables
4.7m
USD
Based on the financial report for Sep 30, 2024, Syndax Pharmaceuticals Inc's Total Receivables amounts to 4.7m USD.
What is Syndax Pharmaceuticals Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
88%
Over the last year, the Total Receivables growth was 12%. The average annual Total Receivables growth rates for Syndax Pharmaceuticals Inc have been 186% over the past three years , 88% over the past five years .
You don't have any saved screeners yet
